- Home
- CHYM vs MDGL Comparison
CHYM vs MDGL Comparison
Compare CHYM & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHYM | MDGL |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4B | 11.5B |
| IPO Year | 2025 | 2005 |
Fundamental Metrics
Financial Performance| Metric | CHYM | MDGL |
|---|---|---|
| Price | $28.46 | $493.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 23 | 19 |
| Target Price | $39.41 | ★ $682.11 |
| AVG Volume (30 Days) | ★ 6.6M | 208.8K |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $2,186,770,000.00 | $180,133,000.00 |
| Revenue This Year | $26.72 | $59.37 |
| Revenue Next Year | $20.84 | $39.35 |
| P/E Ratio | $134.23 | ★ N/A |
| Revenue Growth | ★ 30.69 | N/A |
| 52 Week Low | $15.88 | $393.61 |
| 52 Week High | $35.55 | $615.00 |
Technical Indicators
Market Signals| Indicator | CHYM | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 45.60 | 34.74 |
| Support Level | $24.91 | $455.42 |
| Resistance Level | $33.41 | $502.97 |
| Average True Range (ATR) | 1.23 | 15.43 |
| MACD | -0.42 | -3.47 |
| Stochastic Oscillator | 31.18 | 8.25 |
Price Performance
Historical ComparisonAbout CHYM Chime Financial Inc.
Chime Financial Inc is a financial technology company that provides digital banking services through its proprietary technology platform in partnership with third-party banks. The company offers various financial products and services designed to meet members' financial needs, including spending accounts, liquidity solutions, credit-building tools, savings products, and community-focused financial services.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.